Article
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Research Highlights In The News From ESMO
Summary
- The ESMO 2022 Congress took place in Paris in September 2022, with around 29,000 delegates, including 5,000 online participants.
- The program featured a broad range of topics, including clinical trial results, translational studies, and health policy initiatives.
- A key theme discussed was the optimization of treatment for patients with locally advanced, resectable cancers.
- The phase II NICHE-2 trial showed that neoadjuvant treatment with ipilimumab plus nivolumab was safe and effective in non-metastatic mismatch repair-deficient colon cancer, with no disease recurrence after a median follow-up of 13 months.
- The phase II SWOG S1801 trial demonstrated that neoadjuvant pembrolizumab improved event-free survival and overall survival in patients with stage IIIB–IV melanoma.
- The phase III IPSOS trial found that atezolizumab extended overall survival and reduced adverse events in patients with non-small-cell lung cancer (NSCLC) without actionable driver alterations, compared to standard chemotherapy options.
In September 2022, the ESMO 2022 Congress was held in Paris, marking the return of a highly anticipated annual in-person event for the oncology community. The conference attracted 29,000 delegates, with approximately 5,000 joining the event online.
The congress featured a diverse program, carefully curated by the programme committee to include a wide range of topics such as clinical trial results, translational studies, and health policy initiatives. The three Presidential Symposia exemplified the variety of themes explored during the event, with a significant focus on optimizing treatment for patients with locally advanced, resectable cancers.
ESMO, cancer treatment optimization, NICHE-2 trial, SWOG S1801 trial, IPSOS trial, oncology research
Related Topics
You May Also Like
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Article
Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li, Qian Jiang
Value assessment of PD-1/PD-L1 inhibitors in the treatment of esophageal and gastrointestinal cancers
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary